Denmark's new government will examine whether Wegovy can increase employment rates, adding an economic lens to the obesity treatment debate. The Novo Nordisk drug launched in the country in late 2022, marking one of the first major rollouts of the weight-loss medication.

The pharmaceutical company has already transformed Denmark's economy through significant growth in recent years, despite facing mounting competition. Officials want to test if these medicines can generate economic benefits by boosting workforce productivity and reducing absenteeism.

This study represents a new frontier for weight-loss drugs, moving beyond health outcomes to examine labor market impacts. Denmark's approach could influence how other governments evaluate pharmaceutical investments in chronic disease management, potentially reshaping healthcare economics discussions globally.